Accessibility Menu
Biostar Pharmaceuticals logo

Biostar Pharmaceuticals(OTC) BSPM

Market Cap$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0%
+0.00Today
Biostar Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-13
Biostar Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-06-30
1 month+0%USD 0.002026-06-08
3 month+9,900%USD 0.002026-04-13
Year to date+0%USD 0.002025-12-30
1 year+0%USD 0.002025-07-01
3 year+9,900%USD 0.002023-05-15
5 year-99.91%USD 0.112021-07-14
Since inception-100%USD 36.752008-12-18

Biostar Pharmaceuticals Financials at a Glance

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$317.79K

Net Income (TTM)

$935.00K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

2928.13 (High)

Price

$0.00

Volume

100

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.05

Estimated Earnings Date

N/A

BSPM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biostar Pharmaceuticals

Biostar Pharmaceuticals, Inc. is a developer, manufacturer, and marketer of pharmaceutical products primarily targeting various diseases and conditions in the People's Republic of China. The company specializes in over-the-counter (OTC) and prescription medications, focusing on chronic hepatitis B and other health issues.

Products and Services
  • Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B
  • Ganwang compound paracetamol for common cold relief
  • Tianqi Dysmenorrhea capsule for menstrual pain
Growth Outlook
  • Expansion into traditional Chinese medicine markets is underway
  • Increasing demand for OTC products in China supports growth potential
  • Strategic partnerships may enhance distribution capabilities
Financial Highlights
  • Recent quarterly net income reported at -$125,000
  • Trailing twelve months (TTM) revenue of $0 indicates challenges
  • Current ratio of 1.31 suggests adequate short-term financial health
Biostar Pharmaceuticals, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic medications. The company has a diverse product portfolio that includes both OTC and prescription drugs, catering to a wide range of health conditions. The flagship product, Xin Ao Xing Oleanolic Acid capsule, addresses chronic hepatitis B, a significant health concern in China. The growth outlook for Biostar Pharmaceuticals appears promising, driven by the increasing demand for OTC products and the potential for expansion into traditional Chinese medicine markets. Additionally, the company is exploring strategic partnerships to enhance its distribution capabilities, which could further bolster its market presence. Financially, the company has faced challenges, as indicated by the recent quarterly net income of -$125,000 and a TTM revenue of $0. However, a current ratio of 1.31 suggests that Biostar Pharmaceuticals maintains a reasonable level of short-term financial health, which may provide a buffer as the company navigates its operational hurdles. Overall, Biostar Pharmaceuticals, Inc. presents a unique opportunity within the pharmaceutical sector, particularly for investors interested in companies focused on the Chinese healthcare market. The combination of a diverse product range and potential growth avenues may attract attention from those looking to invest in the evolving landscape of drug manufacturing.
AI Generated • Jul 7, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Xianyang, SN 712046, CN

BSPM Financials

Key Financial Metrics (TTM)

Gross Margin

38.39%

Operating Margin

-149.50%

Net Income Margin

-239.01%

Return on Equity

-14.04%

Return on Capital

-9.09%

Return on Assets

-13.41%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.64M

Volume

100

Avg. Volume

91.065

Financials (TTM)

Gross Profit

-$36.75K

Operating Income

$2.79M

EBITDA

$4.90M

Operating Cash Flow

$8.59M

Capital Expenditure

$0.00

Free Cash Flow

$8.59M

Cash & ST Invst.

$364.97K

Total Debt

$2.43M

Biostar Pharmaceuticals Performance Analysis

Biostar Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42016-12-31-50.7%
Q12017-03-31-100.0%
Q22017-06-30N/A
Q32017-09-30N/A
Biostar Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42016-12-31326.8%
Q12017-03-31-123.6%
Q22017-06-30-31.6%
Q32017-09-3090.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2017YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.50

N/A

Employees

200

N/A

Net Income

-$125.00K

+92.0%

EBITDA

$222.27K

+121.0%

Quarterly Fundamentals

Name
Q3 2017YOY CHG

Total Cash

$364.97K

-44.6%

Total Debt

$2.43M

+0.2%

Accounts Receivable

$461.03K

-92.4%

Inventory

$170.56K

-61.2%

Long Term Debt

$0.00

N/A

Short Term Debt

$2.43M

+0.2%

Return on Assets

-13.41%

N/A

Return on Invested Capital

-9.66%

N/A

Free Cash Flow

-$1.41K

-100.3%

Operating Cash Flow

-$1.41K

-100.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NBRVFNabriva Therapeutics plc
$0.00+0.00%
CWWBFPlant-Based Investment Corp.
$0.00+0.00%
BIOCQBiocept, Inc.
$0.00+0.00%
PEMTFThoughtful Brands Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About BSPM

What is the current price of Biostar Pharmaceuticals?

Biostar Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Biostar Pharmaceuticals?

Over the past 52 weeks, Biostar Pharmaceuticals has traded between $0.00 and $0.05.

How much debt does Biostar Pharmaceuticals have?

Biostar Pharmaceuticals total debt is unavailable.

How much cash does Biostar Pharmaceuticals have on hand?

Biostar Pharmaceuticals does not have cash on hand data available.

What is Biostar Pharmaceuticals’s dividend yield?

Biostar Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services